by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Bio Technology : October 2009
78 Australasian BioTechnology Volume 19 • Number 3 • October 2009 AusBioPEOPLE BioGeelong BioGeelong is an industry network formed to grow the Geelong Region's biotech capability and to maximize the opportunities generated by Geelong's world-class biotech activities. Geelong is a Biotechnology Precinct that boasts several major research and education centers of national & international significance, commercial companies and specialized service providers. BioGeelong aims to work collaboratively with key stakeholders to establish the Geelong Region as a major Victorian biotechnology precinct and a significant player in the State Government's vision to position Victoria as one of the top five biotechnology locations in the world by 2010. Further information is available on BioGeelong's website: www.biogeelong.com.au Hydrix: Our Expertise -- Your Competitive Advantage Hydrix's deeply experienced Biomedical engineering team works with our Clients to reduce the time, cost and risk of bringing innovative products to market. Hydrix provides a wide range of electronic product development services to the biomedical Industry with particular strengths in software/DSP development, low- noise electronic circuit design and wireless connectivity development. Hydrix have worked for companies in Australia and overseas so have deep experience in developing for global markets and gaining the required TGA/FDA/EU approvals. Recent Hydrix projects have included IVD Point of Care products, portable DVT treatment devices and cutting-edge endoscopic appliances. Contact: Peter Lewis -- GM Business Development email@example.com Tel: +61 3 8573 5299 1044A Dandenong Rd Carnegie VIC 3163 Australia KPMG’s R&D Incentives practice KPMG assists organisations to take advantage of the R&D and innovation benefits they are eligible to receive. Our national team of R&D Incentives professionals have extensive industry experience and diverse technical backgrounds across areas including pharmaceutical, biotechnology, science, law, taxation and accounting. This enables our people to provide clear and concise advice and support to clients in the biotechnology sector, and to effectively liaise with the numerous federal and state government agencies and industry bodies that provide funding and other support for innovation and R&D. For further information, contact: David Gelb (National Partner R&D Incentives) on 03-9288 6160 or firstname.lastname@example.org Dr Campbell Spence (Tax Manager, R&D Incentives) on 03-9288 5086 or email@example.com Bio21 The Bio21 Molecular Science and Biotechnology Institute (Bio21 Institute) is a world-class multidisciplinary research centre, specialising in medical, agricultural and environmental biotechnology and nanotechnology. Our vision is to improve human health and the environment through biotechnology innovation and adding value through strategic alliances and collaboration with academia and industry. Located in the heart of Melbourne's 'Parkville Precinct', one of the major education, biomedical research and clinical precincts in the world, exciting opportunities can be explored for industry collaborative ventures, networking and access to technology and expertise -- key factors supporting value creation and commercial outcomes. The Bio21 Institute is the University of Melbourne's flagship contribution to Melbourne's Bio21 Cluster -- research institutes and teaching hospitals working together to create a critical mass for bioscience research and commercialisation. Bio21 Molecular Science and Biotechnology Institute 30 Flemington Road The University of Melbourne, Victoria, 3010, Australia Tel: (+61 3) 834 42220 Web: www.bio21.org Email: firstname.lastname@example.org